Regulation of p53 function and stability by phosphorylation

Molecular and Cellular Biology

Volumn 19, Issue 3, 1999, Pages 1751-1758

  Ashcroft, Margaret ^a   Kubbutat, Michael H G ^a   Vousden, Karen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CELL CYCLE; DNA DAMAGE; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; TUMOR SUPPRESSOR GENE;

EID: 0033020147     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.19.3.1751     Document Type: Article

References (49)

1. Banin, S., L. Moyal, S.-Y. Shieh, Y. Taya, C. W. Anderson, L. Chessa, N. I. Smorodinsky, C. Prives, Y. Reiss, Y. Shiloh, and Y. Ziv. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674-1677.
2. Banks, L., G. Matlashewski, and L. Crawford. 1986. Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem. 159:529-534.
3. Bates, S., and K. H. Vousden. 1996. p53 in signalling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev. 6:1-7.
4. Blaydes, J. P., and T. R. Hupp. 1998. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene 17:1045-1052.
5. Böttger, A., V. Böttger, A. Sparks, L. W.-L., S. F. Howard, and D. P. Lane. 1997. Design of a synthetic Mdm2 binding mini protein that activates the p53 response in vivo. Curr. Biol. 7:860-869.
6. Canman, C. E., D.-S. Lim, K. A. Cimprich, Y. Taya, K. Tamai, K. Sakaguchi, E. Appella, M. B. Kastan, and J. D. Siliciano. 1998. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677-1679.
7. Crook, T., N. J. Marston, E. A. Sara, and K. H. Vousden. 1994. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79:817-827.
8. El-Deiry, W., T. Tokino, V. E. Velculescu, D. B. Levy, V. E. Parson, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumour suppression. Cell 75:817-825.
9. Fiscella, M., S. J. Ullrich, N. Zambrano, M. T. Shields, D. Lin, S. P. Lees-Miller, C. W. Anderson, W. E. Mercer, and E. Appella. 1993. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene 8:1519-1528.
10. Fiscella, M., N. Zambrano, S. J. Ullrich, T. Unger, D. Lin, B. Cho, W. E. Mercer, C. W. Anderson, and E. Appella. 1994. The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities. Oncogene 9:3249-3257.
11. Friedlander, P., Y. Haupt, C. Prives, and M. Oren. 1996. A mutant p53 that discriminated between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16:4961-4971.
12. Fuchs, B., D. O'Connor, L. Fallis, K. H. Scheidtmann, and X. Lu. 1995. p53 phosphorylation mutants retain transcription activity. Oncogene 10:789-793.
13. Fuchs, S. Y., V. Adler, T. Buschmann, Z. Yin, X. Wu, S. N. Jones, and Z. Ronai. 1998. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev. 12:2658-2663.
14. Fuchs, S. Y., V. Adler, M. R. Pincus, and Z. Ronai. 1998. MEKK1/JNK signaling stabilizes and activates p53. Proc. Natl. Acad. Sci. USA 95:10541-10546.
15. Gu, W., and R. G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the C-terminal domain. Cell 90:595-606.
16. Halazonetis, T. D., and A. N. Kandil. 1993. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. 12:5057-5064.
17. Hao, M., A. M. Lowy, M. Kapoor, A. Deffie, G. Liu, and G. Lozano. 1996. Mutation of phosphoserine 389 affects p53 function in vivo. J. Biol. Chem. 271:29380-29385.
18. Haupt, Y., Y. Barak, and M. Oren. 1996. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15:1596-1606.
19. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
20. Hupp, T. R., D. W. Meek, C. A. Midgley, and D. P. Lane. 1992. Regulation of the specific DNA binding function of p53. Cell 71:875-886.
21. Juven, T., Y. Barak, A. Zauberman, D. L. George, and M. Oren. 1993. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8:3411-3416.
22. Kamijo, T., J. D. Weber, G. Zambetti, F. Zindy, M. F. Roussel, and C. J. Sherr. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95:8292-8297.
23. Kapoor, M., and G. Lozano. 1998. Functional activation of p53 via phosphorylation following DNA damage by UV but not γ-irradiation. Proc. Natl. Acad. Sci. USA 95:2834-2837.
24. Kubbutat, M. H. G., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
25. Kubbutat, M. H. G., R. L. Ludwig, M. Ashcroft, and K. H. Vousden. 1998. Regulation of Mdm2 directed degradation by the C-terminus of p53. Mol. Cell. Biol. 18:5690-5698.
26. Kubbutat, M. H. G., and K. H. Vousden. 1998. Keeping an old friend under control: regulation of p53 stability. Mol. Med. Today 4:250-256.
27. Lechner, M. S., D. H. Mack, A. B. Finicle, T. Crook, K. H. Vousden, and L. A. Laimins. 1992. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 11:3045-3052.
28. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
29. Lohrum, M., and K. H. Scheidtmann. 1996. Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes. Oncogene 13:2527-2539.
30. Marston, N. J., T. Crook, and K. H. Vousden. 1994. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 9:2707-2716.
31. Marston, N. J., J. R. Jenkins, and K. H. Vousden. 1995. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene 10:1709-1715.
32. 2 terminus of p53 facilitates transactivation. Cancer Res. 55:2410-2417.
33. Meek, D. W. 1998. Multisite phosphorylation and the integration of stress signals at p53. Cell. Signall. 10:159-166.
34. Meek, D. W. 1994. Post-translational modification of p53. Semin. Cancer Biol. 5:203-210.
35. Midgley, C. A., and D. P. Lane. 1997. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179-1189.
36. Milczarek, G. J., J. Martinez, and G. T. Bowden. 1997. p53 phosphorylation: biochemical and functional consequences. Life Sci. 60:1-11.
37. Milne, D. M., R. H. Palmer, and D. W. Meek. 1992. Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53. Nucleic Acids Res. 20:5565-5570.
38. Pise-Masison, C., M. Radonovich, K. Sakaguchi, E. Appella, and J. N. Brady. 1998. Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells. J. Virol. 72:6348-6355.
39. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
40. Prives, C. 1998. Signaling to p53: breaking the MDM2-p53 circuit. Cell 95:5-8.
41. Rowan, S., R. L. Ludwig, Y. Haupt, S. Bates, X. Lu, M. Oren, and K. H. Vousden. 1996. Specific loss of apoptotic but not cell cycle arrest function in a human tumour derived p53 mutant. EMBO J. 15:827-838.
42. Ryan, K. M., and K. H. Vousden. 1998. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol. Cell. Biol. 18:3692-3698.
43. Sakaguchi, K., J. E. Herrera, S. Saito, T. Miki, M. Bustin, A. Vassilev, C. W. Anderson, and E. Appella. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:2831-2841.
44. Shaw, P., J. Freeman, R. Bovey, and R. Iggo. 1996. Regulation of specific DNA binding by p53: evidence for a role of O-glycosylation and charged residues at the carboxy-terminus. Oncogene 12:921-930.
45. Shieh, S.-Y., M. Ikeda, Y. Taya, and C. Prives. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
46. Siliciano, J. D., C. E. Canman, Y. Taya, K. Sakaguchi, E. Appella, and M. B. Kastan. 1997. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11:3471-3481.
47. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:5001-5014.
48. Vojtesek, B., J. Bartek, C. A. Midgley, and D. P. Lane. 1992. An immunochemical analysis of the human nuclear phosphoprotein p53. J. Immunol. Methods 151:237-244.
49. Waterman, M. J., E. S. Stavridi, J. L. Waterman, and T. D. Halazonetis. 1998. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Genet. 19:175-178.